Hillsdale Investment Management Inc. Purchases New Shares in Enanta Pharmaceuticals, Inc. $ENTA

Hillsdale Investment Management Inc. purchased a new stake in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) during the 4th quarter, HoldingsChannel reports. The firm purchased 422,300 shares of the biotechnology company’s stock, valued at approximately $6,660,000.

Other large investors have also added to or reduced their stakes in the company. Strs Ohio bought a new stake in Enanta Pharmaceuticals in the fourth quarter valued at $50,000. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Enanta Pharmaceuticals by 333.9% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,584 shares of the biotechnology company’s stock valued at $57,000 after acquiring an additional 2,758 shares in the last quarter. Quarry LP bought a new stake in Enanta Pharmaceuticals in the third quarter valued at $81,000. China Universal Asset Management Co. Ltd. boosted its holdings in shares of Enanta Pharmaceuticals by 103.8% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 8,747 shares of the biotechnology company’s stock valued at $105,000 after buying an additional 4,454 shares in the last quarter. Finally, AlphaQuest LLC grew its position in shares of Enanta Pharmaceuticals by 18.1% in the 3rd quarter. AlphaQuest LLC now owns 10,198 shares of the biotechnology company’s stock worth $122,000 after buying an additional 1,562 shares during the period. Institutional investors own 94.99% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on ENTA. Wall Street Zen lowered shares of Enanta Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Sunday. Rodman & Renshaw initiated coverage on shares of Enanta Pharmaceuticals in a research note on Thursday, March 26th. They set a “buy” rating and a $20.00 price objective on the stock. HC Wainwright restated a “buy” rating and issued a $20.00 price objective on shares of Enanta Pharmaceuticals in a report on Tuesday, February 10th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Enanta Pharmaceuticals in a research report on Monday, April 20th. Seven investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $20.29.

Enanta Pharmaceuticals Trading Down 0.5%

NASDAQ ENTA opened at $13.16 on Friday. Enanta Pharmaceuticals, Inc. has a 12 month low of $5.87 and a 12 month high of $17.15. The stock has a market cap of $382.69 million, a P/E ratio of -5.08 and a beta of 1.01. The stock’s fifty day moving average price is $13.61 and its 200-day moving average price is $13.75.

Enanta Pharmaceuticals (NASDAQ:ENTA) last announced its quarterly earnings results on Monday, May 11th. The biotechnology company reported ($0.45) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.46) by $0.01. The company had revenue of $17.16 million for the quarter, compared to analysts’ expectations of $17.03 million. Enanta Pharmaceuticals had a negative net margin of 89.56% and a negative return on equity of 64.04%. As a group, analysts forecast that Enanta Pharmaceuticals, Inc. will post -2.01 earnings per share for the current fiscal year.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc is a biotechnology company headquartered in Watertown, Massachusetts, specializing in the discovery and development of novel, small-molecule drugs targeting viral diseases. Leveraging a proprietary chemistry platform, Enanta has built extensive expertise in designing potent inhibitors of viral proteases and polymerases. The company initially gained recognition through partnerships focused on hepatitis C virus (HCV), where its protease inhibitors formed a key component of ABBVIE’s direct‐acting antiviral regimens.

Building on its HCV experience, Enanta has expanded its pipeline to address respiratory syncytial virus (RSV) and other viral infections.